Effects of selective serotonin re-uptake inhibition on MOrtality, mOrbidity, and mood in Depressed Heart Failure patients | Clinical Trial - MOOD-HF


The goal of the trial was to evaluate escitalopram compared with placebo among patients with chronic systolic heart failure and comorbid depression.

Contribution to the Literature: The MOOD-HF trial showed that escitalopram did not improve death or hospitalization, or improve depression symptoms among patients with chronic heart failure.